Development and application of low-cost T-ARMS-PCR assay for AGT and CYP11B1 gene polymorphisms

1079 Background: Bevacizumab (Beva) is no longer unanimously recommended in the management of breast cancer (BC). Given the absence of faithful predictors of Beva treatment outcome, we made the hypothesis that constitutional gene polymorphisms could play a role in this context. We report the pharmacogenetic ancillary study of the prospective COMET trial conducted in advanced BC patients (pts) receiving first-line Beva associated with paclitaxel. Methods: Relevant targeted gene polymorphisms were analyzed (blood) in 203 prospective pts (mean age 55.3, median follow-up 24 months). VEGFA at positions -2578C > A (rs699947), -1498T > C (rs833061), -634G > C (rs2010963), and 936C > T (rs3025039) were analyzed by PCR-RFLP. VEGFR1 319A > C (rs9582036), VEGFR2 at positions 604C > T (rs2071559), 1192C > T (rs2305948), 1416T > A (rs1870377), IL8 251T > A (rs4073), CYP2C8 139C > T (rs1572080), 399T > C (rs10509681) and ABCB1 at positions 1199 C > TA (rs2229109), 2677G > TAC (rs2032582) were analyzed by Mass-Array Agena. ABCB1 1236C > T (rs1128503) and 3435T > C (rs1045642) were analyzed by pyrosequencing. All fitted HWE. Results: Median progression-free survival (PFS) was 10.8 months. VEGFR1 319A allele was associated with longer PFS (p = 0.03). The VEGFA-1498T allele was significantly associated with both longer overall survival (OS) (p = 0.005) and PFS (p = 0.065). The VEGFA -2578C allele was associated with greater OS (p = 0.002) and PFS (p = 0.071). These two VEGFA polymorphisms were in linkage disequilibrium (p < 0.0001). Multivariate Cox analysis showed that VEGFA -2578 (p = 0.001) and VEGFR2 1416 (p = 0.025) were significant predictors of OS: the score of favorable alleles (VEGFA -2575C and VEGFR2 1416T) was highly associated with OS (p = 0.0003), with median survival at 24 months being 30% for score 0 (95%CI 15-61), 65% for score 1 (95%CI 55-75) and 90% for score 2 (95%CI 67-90). Conclusions: Application of an easy-to-perform low-cost genotyping test may identify strong predictors of Beva outcome in metastatic BC pts. In the current era of precision medicine, a pharmacogenetic-based personalized Beva therapy deserves to be prospectively validated in BC pts. Clinical trial information: 2012-A00244-39.

Download Full-text

P191 Demonstrating performance of a low-cost ultra-rapid PCR assay forTrichomonas vaginaliswith point-of-care applications

Sexually Transmitted Infections ◽

10.1136/sextrans-2012-050601c.191 ◽

2012 ◽

Vol 88 (Suppl 1) ◽

pp. A73.2-A73

Author(s):

D M Pearce ◽

D N Styles

Keyword(s):

Point Of Care ◽

Low Cost ◽

Pcr Assay ◽

Rapid Pcr

Download Full-text

ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms

Transplant Immunology ◽

10.1016/s0966-3274(99)80030-6 ◽

1999 ◽

Vol 7 (2) ◽

pp. 127-128 ◽

Cited By ~ 174

Author(s):

Chris Perrey ◽

Stephen J Turner ◽

Vera Pravica ◽

W Martin Howell ◽

Ian V Hutchinson

Keyword(s):

Gene Polymorphisms ◽

Arms Pcr ◽

Tnf Α ◽

Tgf Β1

Download Full-text

Toward point-of-care diagnostics of Candida auris

10.1101/2020.02.10.20021683 ◽

2020 ◽

Cited By ~ 1

Author(s):

Geoffrey Mulberry ◽

Sudha Chaturvedi ◽

Vishnu Chaturvedi ◽

Brian N. Kim

Keyword(s):

New York ◽

Real Time ◽

Real Time Pcr ◽

Positive Impact ◽

Point Of Care ◽

Low Cost ◽

High Sensitivity ◽

Clinical Samples ◽

Pcr Assay ◽

Candida Auris

AbstractCandida auris is a multidrug-resistant yeast that presents global health threat for the hospitalized patients. Early diagnostic of C. auris is crucial in control, prevention, and treatment. Candida auris is difficult to identify with standard laboratory methods and often can be misidentified leading to inappropriate management. A newly-devised real-time PCR assay played an important role in the ongoing investigation of the C. auris outbreak in New York metropolitan area. The assay can rapidly detect C. auris DNA in surveillance and clinical samples with high sensitivity and specificity, and also useful for confirmation of C. auris cultures. Despite its positive impact, the real-time PCR assay is difficult to deploy at frontline laboratories due to high-complexity set-up and operation. Using a low-cost handheld real-time PCR device, we show that the C. auris can potentially be identified in a low-complexity assay without the need for high-cost equipment. An implementation of low-cost real-time PCR device in hospitals and healthcare facilities is likely to accelerate the diagnosis of C. auris and for control of the global epidemic.

Download Full-text

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay

10.1101/2020.03.06.20032334 ◽

2020 ◽

Cited By ~ 21

Author(s):

James P. Broughton ◽

Xianding Deng ◽

Guixia Yu ◽

Clare L. Fasching ◽

Jasmeet Singh ◽

...

Keyword(s):

Low Cost ◽

Lateral Flow ◽

Lateral Flow Assay ◽

Clinical Samples ◽

Rt Pcr ◽

Pcr Assay ◽

The Us ◽

Comparable Performance ◽

Novel Coronavirus ◽

Reference Samples

ABSTRACTAn outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid (∼30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay.

Download Full-text